Skip to main content
ZEVRA THERAPEUTICS, INC. logo

ZEVRA THERAPEUTICS, INC. — Investor Relations & Filings

Ticker · ZVRA ISIN · US4884452065 LEI · 254900CU6T74V18Y1W18 US Manufacturing
Open in API
Filings indexed 830 across all filing types
Latest filing 2020-05-12 Regulatory Filings
Country US United States of America
Listing US ZVRA

About ZEVRA THERAPEUTICS, INC.

https://zevra.com/

Zevra Therapeutics, Inc. is a commercial-stage biopharmaceutical company dedicated to developing and commercializing therapies for patients with rare diseases. The company focuses on addressing significant unmet medical needs by combining a data-driven scientific approach with a patient-first perspective. Its portfolio includes commercial products such as MIPLYFFA®, an FDA-approved treatment for Niemann-Pick disease type C (NPC), and OLPRUVA®. Zevra Therapeutics also maintains a late-stage clinical pipeline, specializing in advancing promising medicines that face complex clinical and regulatory challenges for conditions with limited or no available treatments.

Recent filings

Filing Released Lang Actions
FORM 8-K
Regulatory Filings Classification · 95% confidence The document is a Form 8-K current report filed with the SEC, dated May 12, 2020. It announces the release of the company's first quarter 2020 financial results and references a press release and a presentation as exhibits. The document itself does not contain the full financial statements or detailed financial data but rather announces the results and provides links to the press release and presentation. The length is 3886 characters, which is relatively short and consistent with an announcement rather than a full report. According to the rules, such a document is best classified as a Regulatory Filing (RNS) because it is a general regulatory announcement and does not contain the full financial report itself.
2020-05-12 English
FORM DEFA14A
Proxy Solicitation & Information Statement Classification · 100% confidence The document is titled 'SCHEDULE 14A INFORMATION' and is identified as a 'Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934.' It is marked as 'Definitive Additional Materials' related to a proxy statement. Proxy statements are materials sent to shareholders to provide information and request votes for meetings. The document does not contain financial statements or detailed financial analysis but is related to shareholder voting information. Therefore, it fits the category of Proxy Solicitation & Information Statement (PSI). The document length is short and does not contain the full proxy statement but additional materials, which still fall under the PSI category rather than a report publication announcement or regulatory filing.
2020-05-08 English
FORM DEF 14A
Proxy Solicitation & Information Statement
2020-05-08 English
FORM 8-K
Regulatory Filings Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a Current Report used to announce significant events or corporate changes. The content includes a press release about the FDA acceptance of a New Drug Application (NDA) and a milestone payment agreement. It does not contain financial statements or detailed financial data, nor is it a full annual or quarterly report. The document is relatively short (4347 characters) and primarily serves as an announcement of a corporate event. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous filings that do not fit other specific categories.
2020-05-04 English
FORM 8-K
Regulatory Filings Classification · 95% confidence The document is a Form 8-K Current Report filed with the SEC, dated April 13, 2020. It announces the setting of the date for the company's 2020 annual meeting of stockholders and provides information about the deadline for stockholder nominations or proposals for the proxy statement. It also states that the annual meeting will be conducted virtually and that further details will be included in the definitive proxy materials. The document does not contain financial statements or detailed financial data, nor is it a full annual report or proxy statement itself. It is an announcement related to the upcoming annual meeting and proxy materials. Given the content and length (3746 characters), it is not a full report but an announcement about the meeting and proxy process. Therefore, the most appropriate classification is Regulatory Filings (RNS), as it is a general regulatory announcement that does not fit other specific categories.
2020-04-13 English
Regulatory Filings 2020
Regulatory Filings
2020-04-13 English

Browse filings by year

18 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.